
Inventiva S.A. (IVA) Stock Forecast & Price Target
Inventiva S.A. (IVA) Analyst Ratings
Bulls say
Inventiva SA is focused on developing lanifibranor for the treatment of non-alcoholic steatohepatitis (NASH), a significant unmet medical need, with encouraging early clinical trial results indicating a 42% improvement in fibrosis compared to a 24% placebo response. The company is strategically positioned within a growing market, leveraging its partnerships with AbbVie and BI to enhance revenue and research capabilities while exploring complementary roles in therapies that target metabolic and cardiovascular benefits for patients with type 2 diabetes. Given the positive clinical developments and a reinforced outlook on the product's potential efficacy and market penetration, Inventiva's growth prospects appear robust within the biopharmaceutical sector.
Bears say
Inventiva SA is a biopharmaceutical company focused on developing lanifibranor for treating non-alcoholic steatohepatitis (NASH), a condition without approved therapies, yet it faces significant challenges that could negatively impact its share performance. The company reported a substantial net loss of €175.9 million, raising concerns about its financial stability and ability to fund its operations amid ongoing development risks associated with its key clinical program, which could face efficacy or safety issues. Furthermore, the reliance on research partnerships for revenue, the potential for clinical trial setbacks, and competition from other therapies compound the risks surrounding Inventiva's growth trajectory, suggesting a precarious future outlook.
This aggregate rating is based on analysts' research of Inventiva S.A. and is not a guaranteed prediction by Public.com or investment advice.
Inventiva S.A. (IVA) Analyst Forecast & Price Prediction
Start investing in Inventiva S.A. (IVA)
Order type
Buy in
Order amount
Est. shares
0 shares